Peripheral Blood BRCA1 Methylation Positively Correlates with Major Alzheimer's Disease Risk Factors

Area of Science:

• Neuroscience
• Genetics
• Biomarkers

Background:

• Central nervous system (CNS) environment can be assessed via peripheral samples.
• Previous work showed BRCA1 promoter hypomethylation in Alzheimer's disease (AD) neuronal cells.
• This study investigates BRCA1 promoter methylation in blood for AD detection.

Purpose of the Study:

• Analyze BRCA1 promoter methylation levels in peripheral blood of AD patients and controls.
• Determine if peripheral methylation changes correlate with AD risk factors.

Main Methods:

• Genomic DNA from peripheral blood was sourced from J-ADNI and Niigata University Hospital.
• Amyloid positivity was determined by PET imaging or CSF Aβ42 levels.
• BRCA1 promoter methylation was quantified using pyrosequencing.

Main Results:

• No significant difference in BRCA1 promoter methylation was observed between AD patients and controls.
• In AD patients, BRCA1 promoter methylation positively correlated with AD risk factors.
• Validation cohort confirmed these findings.

Conclusions:

• Cell-type specific methylome analysis is crucial for CNS biomarker studies.
• Peripheral blood can reflect CNS environmental changes, indicating potential for AD biomarkers.
• Peripheral BRCA1 methylation may serve as a surrogate biomarker for Alzheimer's disease.